The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors

Andrew S. Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The standard of care for malignant gliomas of the brain has changed very little over the last few decades, and does not offer a cure for these rare, but fatal, tumors. The field of immunotherapy has brought potent new drugs into the oncological armamentarium, and is becoming recognized as a potentially important arm in the treatment of glioblastoma for adults. Immune checkpoints are inhibitory receptors found on immune cells that, when stimulated, cause those immune cells to become quiescent. While this is a natural mechanism to prevent excessive inflammatory damage and autoimmunity in otherwise healthy tissues, cancer cells may utilize this process to grow in the absence of targeted immune destruction. Antibodies derived to block the stimulation of these negative checkpoints, allowing immune cells to remain activated and undergo effector function, are a growing area of immunotherapy. These therapies have seen much success in both the preclinical and clinical arenas for various tumors, particularly melanoma and nonsmall-cell lung cancer. Multiple clinical trials are underway to determine if these drugs have efficacy in glioblastoma. Here, we review the current evidence, from early preclinical data to lessons learned from clinical trials outside of glioblastoma, to assess the potential of immune checkpoint inhibition in the treatment of brain tumors and discuss how this therapy may be implemented with the present standard of care.

Original languageEnglish (US)
Pages (from-to)1049-1065
Number of pages17
JournalNeurotherapeutics
Volume14
Issue number4
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Brain Neoplasms
Glioblastoma
Standard of Care
Immunotherapy
Clinical Trials
Neoplasms
Therapeutics
Autoimmunity
Non-Small Cell Lung Carcinoma
Glioma
Pharmaceutical Preparations
Melanoma
Antibodies
Brain

Keywords

  • Brain tumor
  • CTLA-4
  • Glioma
  • Immune checkpoint
  • PD-1

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. / Luksik, Andrew S.; Maxwell, Russell; Garzon-Muvdi, Tomas; Lim, Michael.

In: Neurotherapeutics, Vol. 14, No. 4, 01.10.2017, p. 1049-1065.

Research output: Contribution to journalReview article

Luksik, Andrew S. ; Maxwell, Russell ; Garzon-Muvdi, Tomas ; Lim, Michael. / The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. In: Neurotherapeutics. 2017 ; Vol. 14, No. 4. pp. 1049-1065.
@article{ea92536b53184eb5aaf241032bb89053,
title = "The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors",
abstract = "The standard of care for malignant gliomas of the brain has changed very little over the last few decades, and does not offer a cure for these rare, but fatal, tumors. The field of immunotherapy has brought potent new drugs into the oncological armamentarium, and is becoming recognized as a potentially important arm in the treatment of glioblastoma for adults. Immune checkpoints are inhibitory receptors found on immune cells that, when stimulated, cause those immune cells to become quiescent. While this is a natural mechanism to prevent excessive inflammatory damage and autoimmunity in otherwise healthy tissues, cancer cells may utilize this process to grow in the absence of targeted immune destruction. Antibodies derived to block the stimulation of these negative checkpoints, allowing immune cells to remain activated and undergo effector function, are a growing area of immunotherapy. These therapies have seen much success in both the preclinical and clinical arenas for various tumors, particularly melanoma and nonsmall-cell lung cancer. Multiple clinical trials are underway to determine if these drugs have efficacy in glioblastoma. Here, we review the current evidence, from early preclinical data to lessons learned from clinical trials outside of glioblastoma, to assess the potential of immune checkpoint inhibition in the treatment of brain tumors and discuss how this therapy may be implemented with the present standard of care.",
keywords = "Brain tumor, CTLA-4, Glioma, Immune checkpoint, PD-1",
author = "Luksik, {Andrew S.} and Russell Maxwell and Tomas Garzon-Muvdi and Michael Lim",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s13311-017-0513-3",
language = "English (US)",
volume = "14",
pages = "1049--1065",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors

AU - Luksik, Andrew S.

AU - Maxwell, Russell

AU - Garzon-Muvdi, Tomas

AU - Lim, Michael

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The standard of care for malignant gliomas of the brain has changed very little over the last few decades, and does not offer a cure for these rare, but fatal, tumors. The field of immunotherapy has brought potent new drugs into the oncological armamentarium, and is becoming recognized as a potentially important arm in the treatment of glioblastoma for adults. Immune checkpoints are inhibitory receptors found on immune cells that, when stimulated, cause those immune cells to become quiescent. While this is a natural mechanism to prevent excessive inflammatory damage and autoimmunity in otherwise healthy tissues, cancer cells may utilize this process to grow in the absence of targeted immune destruction. Antibodies derived to block the stimulation of these negative checkpoints, allowing immune cells to remain activated and undergo effector function, are a growing area of immunotherapy. These therapies have seen much success in both the preclinical and clinical arenas for various tumors, particularly melanoma and nonsmall-cell lung cancer. Multiple clinical trials are underway to determine if these drugs have efficacy in glioblastoma. Here, we review the current evidence, from early preclinical data to lessons learned from clinical trials outside of glioblastoma, to assess the potential of immune checkpoint inhibition in the treatment of brain tumors and discuss how this therapy may be implemented with the present standard of care.

AB - The standard of care for malignant gliomas of the brain has changed very little over the last few decades, and does not offer a cure for these rare, but fatal, tumors. The field of immunotherapy has brought potent new drugs into the oncological armamentarium, and is becoming recognized as a potentially important arm in the treatment of glioblastoma for adults. Immune checkpoints are inhibitory receptors found on immune cells that, when stimulated, cause those immune cells to become quiescent. While this is a natural mechanism to prevent excessive inflammatory damage and autoimmunity in otherwise healthy tissues, cancer cells may utilize this process to grow in the absence of targeted immune destruction. Antibodies derived to block the stimulation of these negative checkpoints, allowing immune cells to remain activated and undergo effector function, are a growing area of immunotherapy. These therapies have seen much success in both the preclinical and clinical arenas for various tumors, particularly melanoma and nonsmall-cell lung cancer. Multiple clinical trials are underway to determine if these drugs have efficacy in glioblastoma. Here, we review the current evidence, from early preclinical data to lessons learned from clinical trials outside of glioblastoma, to assess the potential of immune checkpoint inhibition in the treatment of brain tumors and discuss how this therapy may be implemented with the present standard of care.

KW - Brain tumor

KW - CTLA-4

KW - Glioma

KW - Immune checkpoint

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85014162670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014162670&partnerID=8YFLogxK

U2 - 10.1007/s13311-017-0513-3

DO - 10.1007/s13311-017-0513-3

M3 - Review article

C2 - 28258545

AN - SCOPUS:85014162670

VL - 14

SP - 1049

EP - 1065

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -